Suttorp, Norbert

Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment

Schulte-Schrepping, J., Reusch, N., Paclik, D., Baßler, K., Schlickeiser, S., Zhang, B., Krämer, B., Krammer, T., Brumhard, S., Bonaguro, L., et al. (2020) · Cell

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 1,461

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., et al. (2020) · Nature

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 1,310

COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis

Chua, R. L., Lukassen, S., Trump, S., Hennig, B. P., Wendisch, D., Pott, F., Debnath, O., Thürmann, L., Kurth, F., Völker, M. T., et al. (2020) · Nature Biotechnology

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 1,035

Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation

Fiedler, U., Reiss, Y., Scharpfenecker, M., Grunow, V., Koidl, S., Thurston, G., Gale, N. W., Witzenrath, M., Rosseau, S., Suttorp, N., et al. (2006) · Nature Medicine

Angiogenesis and VEGF in CancerCell Adhesion Molecules Research

Cited by 933

Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection

Messner, C. B., Demichev, V., Wendisch, D., Michalick, L., White, M., Freiwald, A., Textoris-Taube, K., Vernardis, S. I., Egger, A.-S., Kreidl, M., et al. (2020) · Cell Systems

Advanced Proteomics Techniques and ApplicationsCOVID-19 Clinical Research Studies

Cited by 561

SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis

Wendisch, D., Dietrich, O., Mari, T., von Stillfried, S., Ibarra, I. L., Mittermaier, M., Mache, C., Chua, R. L., Knoll, R., Timm, S., et al. (2021) · Cell

COVID-19 Clinical Research StudiesInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Cited by 528

A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model

Kreye, J., Reincke, S. M., Kornau, H.-C., Sánchez-Sendin, E., Corman, V. M., Liu, H., Yuan, M., Wu, N. C., Zhu, X., Lee, C.-C. D., et al. (2020) · Cell

SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 347

IFNs Modify the Proteome of Legionella-Containing Vacuoles and Restrict Infection Via IRG1-Derived Itaconic Acid

Naujoks, J., Tabeling, C., Dill, B. D., Hoffmann, C., Brown, A. S., Kunze, M., Kempa, S., Peter, A., Mollenkopf, H.-J., Dorhoi, A., et al. (2016) · PLOS Pathogens

Legionella and Acanthamoeba researchinterferon and immune responses

Cited by 261

Complement activation induces excessive T cell cytotoxicity in severe COVID-19

Georg, P., Astaburuaga-García, R., Bonaguro, L., Brumhard, S., Michalick, L., Lippert, L. J., Kostevc, T., Gäbel, C., Schneider, M., Streitz, M., et al. (2022) · Cell

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 218

A time-resolved proteomic and prognostic map of COVID-19

Demichev, V., Tober-Lau, P., Lemke, O., Nazarenko, T., Thibeault, C., Whitwell, H., Röhl, A., Freiwald, A., Szyrwiel, L., Ludwig, D., et al. (2021) · Cell Systems

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 200

Role of nitric oxide and phosphodiesterase isoenzyme II for reduction of endothelial hyperpermeability

Suttorp, N., Hippenstiel, S., Fuhrmann, M., Krull, M., & Podzuweit, T. (1996) · American Journal of Physiology-Cell Physiology

Phosphodiesterase function and regulationNitric Oxide and Endothelin Effects

Cited by 133

Influenza vaccination is associated with reduced severity of community-acquired pneumonia

Tessmer, A., Welte, T., Schmidt-Ott, R., Eberle, S., Barten, G., Suttorp, N., & Schaberg, T. (2011) · European Respiratory Journal

Pneumonia and Respiratory InfectionsInfluenza Virus Research Studies

Cited by 65

KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma

Frost, N., Kollmeier, J., Vollbrecht, C., Grah, C., Matthes, B., Pultermann, D., von Laffert, M., Lüders, H., Olive, E., Raspe, M., et al. (2021) · Translational Lung Cancer Research

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 61